The fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious ...

Those with ALS have an average survival of around two to five years from diagnosis, with most ALS patients dying from ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company, has announced that the USFDA has granted ‘Fast Track ...

The ‘Easiest Exam’ campaign promotes early detection of breast cancer, amassing over 164 million impressions and encouraging ...

Zydus Lifesciences is on analysts' radar. The stock rose nearly 2% on Wednesday after reporting mixed fourth-quarter results.

Zydus Lifesciences Q4 stuns with margin guidance, but brokerages trim targets — stock ends at Rs 890. Should you follow ...

Devan Choksey is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1069 in its research report dated May 26, 2025.

Zydus Lifesciences' impactful campaign promotes self-breast examination for early detection of breast cancer, reaching ...

Zydus Lifesciences is innovating a single-device for semaglutide. This device can deliver multiple strengths of the drug. It ...

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter ...

Results: Net profit for the quarter fell 1% from the year-ago period to ₹1,171 crore. The company reported a one-time loss of ...